Wheel Axle Market is Projected to Grow at a 4.1% CAGR, Reaching US$ 99.73 Billion by 2034 | Fact.MR Report

Rockville, MD , Nov. 18, 2024 (GLOBE NEWSWIRE) — According to a recently updated industry report by Fact.MR, the global wheel axle market is estimated to reach US$ 66.73 billion in 2024 and advance further at a CAGR of 4.1% from 2024 to 2034.

An axle is a central shaft for a rotating wheel that can be attached to the wheels, rotate with them, or remain stationary while the wheels rotate around it. This is a critical component of any wheeled vehicle and can be classified as front, rear, full-floating, or semi-floating axles.

In developing countries, rapid expansion of the industrial sector and improved logistics are constantly pushing the demand for commercial vehicles, driving up the market for wheel axles in parallel. Governments are focusing on expanding transit facilities due to population growth and urbanization, which is putting added pressure on the transport and automobile sectors.

Rolling stock, including locomotives, carriages, and wagons, is in substantial demand due to its high transportation capacity compared to other modes. The market is mainly expanding due to growth in the automotive and transportation industries, electric axles in trailers, and emission regulations for transport refrigeration units. East Asia and North America will be key regional markets for wheel axle sales, together accounting for around two-thirds market share throughout the next ten years.

For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=4559


Key Takeaways from Market Study

  • The global market for wheel axles is projected to expand at a CAGR of 1% from 2024 to 2034.
  • The market has been forecasted to climb to a value of US$ 99.73 billion by the end of 2034.
  • The market in the United States is expected to reach a value of US$ 7.53 million in 2024.
  • Japan is projected to occupy a market share of 6% in East Asia in 2024.
  • Revenue from the rail end-use segment is forecasted to reach US$ 25.03 billion by the end of 2034.
  • The market in East Asia is analyzed to expand at a CAGR of 4.6% from 2024 to 2034.

“Growing industrial sectors and need for improved logistics operations in developing countries driving demand for commercial vehicles, which will also push the need for wheel axles over the coming years,” says a Fact.MR analyst.

Leading Players Driving Innovation in the Wheel Axle Market

Key players in the wheel axle market are Dana Incorporated, American Axle and Manufacturing Inc., Daimler AG, Meritor Inc., GNA Group, Melrose Industries Plc., ZF Friedrichshafen AG, BorgWarner Inc., Hyundai Wia Corporation, Talbros Engineering Limited. 

Increasing Demand for More Efficient and Durable Axle Systems

Global vehicle manufacturing is increasing, particularly in emerging markets as more vehicles enter the market, demand for axles rises in tandem. The rapid growth of the EV market necessitates specialized axle designs. The emphasis is on lightweight axles to improve range and efficiency.

There is also a strong demand for more efficient and durable axle systems, which is fueling interest in SUVs and off-road vehicles. There is also a need for axles that can withstand rough terrain. Globally, aging vehicle fleets are increasing demand for replacement axles. Increased logistics and transportation activities are increasing the demand for heavy-duty axles.

Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=S&rep_id=4559
Wheel Axle Industry News:

  • The Protec independent front suspension for motor coaches, built especially to support large loads, was introduced by Meritor Inc. in June 2022.
  • ai, a self-driving startup, said in July 2022 that it would collaborate with Sany Heavy Industry to mass-produce self-driving trucks in China. With their sophisticated axle and drivetrain systems and “Level 4” autonomous driving technology, these trucks will be able to drive themselves fully on city streets and highways.

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the wheel axle market for 2019 to 2023 and forecast statistics for 2024 to 2034.

The study divulges insights into the wheel axle market based on end use (vehicles, rail) and drive torque (below 300 Nm, 300 to 600 Nm, 600 to 900 Nm, 900 to 1,200 Nm, 1,200 to 1,500 Nm, above 1,500 Nm), across seven major regions of the world (North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and MEA).

Check out More Related Studies Published by Fact.MR:

Wheel and Tire Service Equipment Market: Size is estimated to reach valuation of US$ 4,046.6 Million in 2023 and will top US$ 5,893.9 Million by 2033, growing with a CAGR of around 3.8% from 2023-2033.

Trailer Axle Market: Size is forecasted to increase from US$ 8.42 billion in 2024 to US$ 13.95 billion by 2034-end, expanding at a CAGR of 5.2% over the next ten years.

Wheel Balancing Weight MarketSize is anticipated to grow from a 2024 valuation of US$ 727.8 million to US$ 1.35 billion by the end of 2034, with a compound annual growth rate (CAGR) of 6.4%.

Automotive Wheel MarketSize is forecasted to reach US$ 34.42 billion in 2024, further increasing at a CAGR of 6.4% to end up at US$ 63.95 billion by 2034.

Motorcycle Suspension System MarketSize is valued at US$ 499.8 million in 2023. Expanding at a CAGR of 6.1%, worldwide sales of motorcycle suspension systems are projected to reach US$ 903.6 million by 2033-end.

Trailer Suspension System MarketSize is estimated to be valued at US$ 4,089.7 million in 2024. Projections indicate a steady expansion with a CAGR of 5.1%, and is forecast to reach the valuation of US$ 6,725.3 million from 2024 to 2034

About Us:

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.

With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay competitive.

Contact:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Teamsales@factmr.com
Follow Us: LinkedIn | Twitter | Blog


Primary Logo

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Stock market today: Dow slips, Nasdaq pops as Tesla and bitcoin shine

US stock futures traded mixed on Monday amid fading optimism for interest-rate cuts, as investors looked ahead to Nvidia (NVDA) earnings to test the health of the AI trade.

Dow Jones Industrial Average futures (YM=F) slipped roughly 0.2%, while S&P 500 futures (ES=F) were broadly flat. Contracts on the tech-heavy Nasdaq 100 (NQ=F) rose 0.3%, buoyed by a jump in Tesla (TSLA) stock.

Stocks are starting the week on the back foot as the prospect of higher-for-longer rates holds post-election bullishness in check. The S&P 500 has reversed half of its Trump-fueled rally after sharp weekly losses for the major gauges, led by tech.

Signs of a robust economy, combined with comments from Federal Reserve Chair Jerome Powell, have prompted investors to downsize expectations for rate cuts. After the big macro and political events of recent days, the week brings few economic releases seen as likely to reset those calculations.

Read more: What the Fed rate cut means for bank accounts, CDs, loans, and credit cards

Given that, eyes are now on Nvidia’s results on Wednesday for insight into the strength of the AI trade, which has helped drive the S&P 500’s gains over the past year. Production of its flagship Blackwell chip is in focus, especially after The Information reported the next-generation AI chip has run into problems with overheating. Nvidia shares were down over 2% in premarket trading.

Elsewhere in tech, EV maker Tesla’s shares rose almost 7% in the wake of a Bloomberg report that President-elect Donald Trump’s team is looking to ease US rules for self-driving vehicles.

Wall Street continues to monitor Trump’s picks for his cabinet, after his choice of Robert F. Kennedy Jr for top health official rattled vaccine stocks. The incoming president has named Brendan Carr, a critic of Big Techs such as Meta and Apple, as chairman of the Federal Communications Commission. The wait is now on to learn who will win the frenzied race to become Trump’s Treasury Secretary.

Meanwhile, bitcoin (BTC-USD) — a key Trump trade — has rebounded from its biggest retreat since the election at the weekend. The cryptocurrency was trading above $90,000 early on Monday.

LIVE 2 updates

  • Brian Sozzi

    Goldman weighs in on potential Trump tariff impact

    Wall Street’s 2025 outlook reports are trickling in, and one keyword search I am doing, of course, is tariffs. Any tariffs imposed on China or Europe by Trump could impact the economy and the outlook for Fed policy.

    Goldman Sachs chief economist Jan Hatzius is out this morning downplaying the potential economic impact of tariffs. Hatzius reasons that tariffs would be more of a one-time hit to growth and inflation, and won’t derail further rate cuts from the Fed in 2025.

    Hatzius says:

  • Brian Sozzi

    Let Nvidia mania begin

    To say expectations on Nvidia (NVDA) are sky high into its Wednesday earnings print is an understatement.

    They are super, extra sky high!

    Nvidia has outperformed the S&P 500 (^GSPC) by 172% year to date and 5% in the last month, points out EvercoreISI analyst Mark Lipacis. The stock trades on a forward P/E multiple of 37 times, a 54% premium to the S&P 500.

    The expectations have Wall Street hedging their bets a bit on Nvidia into the release. Here’s Lipacis in a client note this morning:

    I touched on Nvidia’s valuation in a recent chat on my Opening Bid podcast with Bank of America analyst Vivek Arya (video below). Arya makes some good points on how Nvidia’s stock tends to trade around certain valuation levels.

This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

  • Citigroup analyst Atif Malik initiated coverage on Astera Labs, Inc. ALAB with a Buy rating and announced a price target of $120. Astera Labs shares closed at $86.45 on Friday. See how other analysts view this stock.
  • Jones Trading analyst Catherine Novack initiated coverage on Korro Bio, Inc. KRRO with a Buy rating and announced a price target of $130. Korro Bio shares closed at $47.56 on Friday. See how other analysts view this stock.
  • B of A Securities analyst Ruplu Bhattacharya initiated coverage on Ingram Micro Holding Corporation INGM with a Buy rating and announced a price target of $30. Ingram Micro shares closed at $22.75 on Friday. See how other analysts view this stock.
  • RBC Capital analyst Victoria McCulloch initiated coverage on TechnipFMC plc FTI with an Outperform rating and announced a price target of $37. TechnipFMC shares closed at $28.18 on Friday. See how other analysts view this stock.
  • JMP Securities analyst Silvan Tuerkcan initiated coverage on enGene Holdings Inc. ENGN with a Market Outperform rating and announced a price target of $18. enGene shares closed at $7.63 on Friday. See how other analysts view this stock.

Considering buying FTI stock? Here’s what analysts think:

Read More:

Market News and Data brought to you by Benzinga APIs

Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66th Annual American Society of Hematology Meeting and Exposition

Raised approximately $19.4 million with potential to raise up to an additional $73.3 million

Company to hold webcast and conference call at 8:30 AM ET today

FLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. CLRB, a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended September 30, 2024, and provided a corporate update.

“We achieved important clinical, operational and commercial corporate objectives during the quarter. We reported topline results from the CLOVER-WaM pivotal study in WM and look forward to filing our NDA submission with a request for accelerated regulatory approval in the coming months,” said James Caruso, president and CEO of Cellectar Biosciences. “In addition to our lead iopofosine I 131 program, we plan to further advance the value of our phospholipid radioconjugate pipeline and are preparing alpha and Auger PRCs for initiation of solid tumor clinical studies as business conditions allow.”

Third Quarter and Recent Corporate Highlights

  • Reported positive results from the Phase 2 CLOVER-WaM pivotal study evaluating iopofosine I 131, the company’s potentially first-in-class, targeted radiotherapeutic candidate, for the treatment of relapsed/refractory Waldenstrom’s macroglobulinemia (WM). These results support the company’s planned filing of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the near term.
  • Selected to present data from the CLOVER-WaM study evaluating iopofosine I 131 in patients with WM at the upcoming 66th Annual American Society of Hematology Meeting and Exposition (ASH), in an oral presentation session. Details of the oral presentation are as follows:
    • Abstract Title: Iopofosine I 131 in Previously Treated Patients with Waldenström Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM™)
    • Session Name: 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Clinical Trials for Marginal Zone Lymphoma, Waldenstrom’s Macroglobulinemia and Hairy Cell Leukemia
    • Session Date: Monday, December 9, 2024
    • Presentation Time: 3:15 PM PST
  • Delivered oral and poster presentations at the 12th International Workshop on Waldenstrom’s Macroglobulinemia (IWWM) in October 2024 that highlighted the activity of iopofosine I 131 in WM.
    • Oral presentation: Session XXII Clinical Trials in Progress for WM: Multi-center trial of iopofosine I-131 in relapsed/refractory WM
    • Poster presentation: Treatment With iopofosine I 131 in a Patient With Bing-Neel Syndrome, A Rare Manifestation of Waldenström Macroglobulinemia: A Case Report
  • Advanced sales, marketing and medical planning activities to support iopofosine I 131 commercialization
  • Partnered with key national and regional community cancer networks to better understand the WM disease landscape, to advance iopofosine I 131 for WM patients in the community setting
  • Established collaboration with the City of Hope Cancer Center to evaluate iopofosine I 131 in mycosis fungoides, a cutaneous T-cell lymphoma
  • Executed supply and manufacturing agreements, further strengthening our multi-sourced supply network:
    • Commercial finished product supply of iopofosine I 131 with SpectronRx
    • Pre-clinical and clinical supply of alpha-emitting actinium 225 isotope with Northstar Medical Radioisotopes
  • Raised $19.4 million through warrant exercises and issued new milestone-based warrants with the potential to raise up to an additional $73.3 million. Funds generated from the execution of these new warrants will further advance the company’s commercialization plans for iopofosine I 131 in the treatment of WM and support future clinical development.

Third Quarter 2024 Financial Highlights

  • Cash and Cash Equivalents: As of September 30, 2024, the company had cash and cash equivalents of $34.3 million, including 19.4 million ($17.5 million, net) raised through investor exercises of Tranche B warrants and the purchase of new warrants in July 2024, compared to $9.6 million as of December 31, 2023. The company believes its cash balance as of September 30, 2024, is adequate to fund its basic budgeted operations into the second quarter of 2025.
  • Research and Development Expenses: R&D expenses for the three months ended September 30, 2024, were approximately $5.5 million, compared to approximately $7.0 million for the three months ended September 30, 2023. The overall decrease was primarily a result of the conclusion of patient enrollment in our WM pivotal study having occurred earlier in the year, partially offset by increased activity in our ongoing pediatric trial and an increase in personnel.
  • General and Administrative Expenses: G&A expenses for the three months ended September 30, 2024, were approximately $7.8 million, compared to approximately $2.4 million for the same period in 2023. The increase was primarily driven by costs associated with the development of infrastructure necessary to support commercialization upon anticipated NDA approval, including the related marketing and personnel cost.

Conference Call & Webcast Details
Cellectar management will host a conference call and webcast today, November 18, 2024, at 8:30 AM Eastern Time to discuss these results and answer questions. Stockholders and other interested parties may participate in the conference call by dialing 1-800-717-1738. A live webcast of the conference call can be accessed in the “Events & Presentations” section of Cellectar’s website at www.cellectar.com. A recording of the webcast will be available and archived on the Company’s website for approximately 90 days.

About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC™) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.

The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: X, LinkedIn, and Facebook.

Forward Looking Statements Disclaimer
This news release contains forward-looking statements. You can identify these statements by our use of words such as “may,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” “continue,” “plans,” or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes including our expectations regarding the CLOVER-WaM pivotal trial. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to maintain orphan drug designation in the United States for iopofosine, the volatile market for priority review vouchers, our pharmaceutical collaborators’ ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K/A for the year ended December 31, 2023, and our Form 10-Q for the quarter ended September 30, 2024. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

MEDIA:
Claire LaCagnina
Bliss Bio Health
315-765-1462
clacagnina@blissbiohealth.com

INVESTORS:
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com

+++ TABLES TO FOLLOW +++

             
CELLECTAR BIOSCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
             
    September 30,    December 31, 
    2024     2023  
ASSETS            
CURRENT ASSETS:            
Cash and cash equivalents   $ 34,263,371     $ 9,564,988  
Prepaid expenses and other current assets     1,635,818       888,225  
Total current assets     35,899,189       10,453,213  
Property, plant & equipment, net     910,131       1,090,304  
Operating lease right-of-use asset     454,166       502,283  
Other long-term assets     29,780       29,780  
TOTAL ASSETS   $ 37,293,266     $ 12,075,580  
             
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)            
CURRENT LIABILITIES:            
Accounts payable and accrued liabilities   $ 8,304,311     $ 9,178,645  
Warrant liability     11,929,242       16,120,898  
Lease liability, current     80,821       58,979  
Total current liabilities     20,314,374       25,358,522  
Long-term lease liability, net of current portion     431,929       494,003  
TOTAL LIABILITIES     20,746,303       25,852,525  
COMMITMENTS AND CONTINGENCIES            
MEZZANINE EQUITY:            
Series D preferred stock, 111.11 shares authorized, issued and outstanding as of September 30, 2024 and December 31, 2023     1,382,023       1,382,023  
STOCKHOLDERS’ EQUITY (DEFICIT):            
Series E-2 preferred stock, 1,225.00 shares authorized; 149.60 and 319.76 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively     2,188,434       4,677,632  
Series E-3 preferred stock, 2,205.00 shares authorized; 202.50 and 0 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively     4,369,317        
Series E-4 preferred stock, 1,610.00 shares authorized; 714.00 and 0 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively     7,057,793        
Common stock, $0.00001 par value; 170,000,000 shares authorized; 40,566,534 and 20,744,110 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively     406       207  
Additional paid-in capital     246,536,080       182,924,210  
Accumulated deficit     (244,987,090 )     (202,761,017 )
Total stockholders’ equity (deficit)     15,164,940       (15,158,968 )
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)   $ 37,293,266     $ 12,075,580  
 
                         
CELLECTAR BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
                         
    Three Months Ended September 30,    Nine Months Ended September 30, 
    2024     2023     2024     2023  
OPERATING EXPENSES:                        
Research and development   $ 5,493,496     $ 7,034,656     $ 19,927,019     $ 19,528,898  
General and administrative     7,834,181       2,378,804       19,105,853       6,883,866  
Total operating expenses     13,327,677       9,413,460       39,032,872       26,412,764  
                         
LOSS FROM OPERATIONS     (13,327,677 )     (9,413,460 )     (39,032,872 )     (26,412,764 )
                         
OTHER INCOME (EXPENSE):                        
Warrant issuance expense     (7,743,284 )     (470,000 )     (7,743,284 )     (470,000 )
Gain (loss) on valuation of warrants     6,088,355       (7,688,028 )     3,583,440       (8,254,649 )
Interest income     317,887       51,110       966,643       247,925  
Total other income (expense)     (1,337,042 )     (8,106,918 )     (3,193,201 )     (8,476,724 )
NET LOSS   $ (14,664,719 )   $ (17,520,378 )     (42,226,073 )   $ (34,889,488 )
NET LOSS PER SHARE — BASIC   $ (0.37 )   $ (1.55 )     (1.21 )   $ (3.09 )
NET LOSS PER SHARE — DILUTED   $ (0.40 )   $ (1.55 )     (1.39 )   $ (3.09 )
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING — BASIC     39,335,924       11,308,738       34,850,441       11,277,231  
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING — DILUTED     39,794,220       11,308,738       35,545,500       11,277,231  


Primary Logo

Market News and Data brought to you by Benzinga APIs

EXCLUSIVE: Binance CEO Richard Teng Says 2025 Will Outshine 2024 For Crypto

Binance CEO Richard Teng on Monday expressed strong optimism for the future of the cryptocurrency industry, predicting that 2025 will surpass the growth and adoption seen in 2024.

Teng’s comments come amid growing institutional interest and regulatory clarity, which he believes are setting the stage for a transformative year for digital assets.

What Happened: “2024 has been a good year, but I firmly believe 2025 will be even better,” Teng told Benzinga in an interview.

Highlighting Bitcoin‘s BTC/USD performance and the factors driving market growth, he pointed to the approval of Bitcoin ETFs as a significant catalyst.

“Earlier this year, we saw Bitcoin ETFs approved in the U.S. and globally, from Brazil to Hong Kong and Australia. The net inflow into Bitcoin ETFs has already surpassed that of gold ETFs within a year, demonstrating the immense pent-up demand,” Teng added.

Teng emphasized Bitcoin’s continued ascent as more institutions and governments embrace the asset.

“This year, we’ve seen a significant uptick in institutional interest, with sovereign wealth funds and pension funds beginning to allocate Bitcoin reserves. This is a major positive for the industry as we move into 2025,” he said.

He also noted that macroeconomic factors like controlled inflation and reduced interest rates globally will further bolster Bitcoin’s growth.

Addressing the role of meme coins in the burgeoning crypto industry , Teng acknowledged their appeal to new retail investors entering the market.

“Meme coins account for about 12% of trading volume, which is quite significant,” Teng noted.

He described them as a gateway for beginners, saying, “Meme coins are fun, exciting, and relatable to young adults. They’re often the first step into crypto for many novice investors.”

Responding to allegations of Binance allegedly listing pump-and-dump meme coin schemes, he said the crypto exchange followed stringent listing criteria, ensuring only projects with strong fundamentals make it onto their platform.

“If you look at some of these projects, they’re not just about where they are today but where they aim to go in the future,” he said.

Teng attributed the industry’s growth to increasing institutional involvement and regulatory clarity.

“Close to one-third of global regulators now have frameworks for crypto. This clarity is critical for mass adoption,” he explained.

Benzinga Future of Digital Assets conference

Also Read: Dogecoin To $1 By December? Probably Not Happening, Polymarket Traders Say

He added that 2024 witnessed a doubling of institutional onboarding at Binance compared to the previous year, with the trend expected to continue into 2025.

“Institutions spend months conducting due diligence before entering this space. Now that the U.S. and global environments are more favorable, we expect even more institutions to onboard in 2025,” Teng said.

Teng stressed the importance of working with governments to develop smart regulatory frameworks that balance innovation with risk management.

“We are the most licensed and regulated crypto exchange globally, with 20 licenses across the world, including in India and Argentina,” Teng stated.

He believes that a collaborative approach with regulators can unlock the full potential of blockchain and digital assets, making them foundational technologies for global economic growth.

“Crypto has changed the lives of so many people, especially where banking systems are expensive or inaccessible,” he said.

He added that blockchain’s transparency and efficiency are reshaping industries from supply chain management to real estate.

He also emphasized the importance of regulatory clarity for the growth of the cryptocurrency industry.

Teng highlighted the challenges posed by the SEC’s enforcement-led approach in recent years, which created uncertainty and hindered innovation.

“Regulatory frameworks must strike a balance between managing risks and supporting innovation,” he said, adding that pro-crypto regulators who understand the transformative potential of blockchain technology can foster an environment conducive to mass adoption.

What’s Next: Teng’s insights come as the crypto industry prepares for significant events, including Benzinga’s Future of Digital Assets conference on Nov. 19.

Read Next:

Image: Shutterstock

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Ligament Stabilizer Market Size to Exceed USD 4.6 billion by 2031, at a CAGR of 6.7% | Transparency Market Research, Inc.

Wilmington, Delaware, United States, Transparency Market Research Inc. -, Nov. 18, 2024 (GLOBE NEWSWIRE) — The global ligament stabilizer market (인대 안정제 시장) is estimated to flourish at a CAGR of from 6.7% 2023 to 2031. Transparency Market Research projects that the overall sales revenue for ligament stabilizer is estimated to reach US$ 4.6 billion by the end of 2031.  The integration of ligament stabilizer consultations and recommendations into telehealth platforms is gaining prominence. This trend not only facilitates remote patient monitoring but also enhances accessibility to expert advice, optimizing post-injury care.

Increasing efforts in patient education initiatives contribute to better awareness of preventive measures and early intervention strategies. Empowering individuals with knowledge about the importance of ligament support fosters proactive healthcare practices, influencing market growth. Evolving biomechanical research is influencing the design and functionality of ligament stabilizers. Insights into joint dynamics and movement patterns are driving the development of next-generation stabilizing devices, offering improved performance and patient outcomes.

The integration of smart technologies, such as sensors and connectivity features, into ligament stabilizers is an emerging trend. These technological enhancements provide real-time data on joint movement, aiding in personalized rehabilitation and optimizing recovery. Increasing emphasis on preventive healthcare, especially in the context of musculoskeletal health, is indirectly influencing the ligament stabilizer market. Proactive measures to prevent ligament injuries align with broader healthcare trends, driving demand for preventive solutions.

Request Sample PDF of the Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=38513

Key Findings of the Market Report

  • Grade 2 ligament injuries dominate the ligament stabilizer market, driving demand for effective support and rehabilitation solutions in orthopedic care.
  • Online sales emerge as the leading sales channel for ligament stabilizers, offering convenience, extensive product choices, and accessibility for consumers.
  • Knee braces & supports dominate the ligament stabilizer market, representing the most sought-after product type for joint support and injury prevention.

Ligament Stabilizer Market: Competitive Landscape

The ligament stabilizer market thrives in a competitive landscape defined by key players committed to orthopedic advancements. Companies like DJO Global, Ossur, and Bauerfeind AG dominate with innovative stabilizing solutions. Intense R&D activities focus on product enhancements, ensuring optimal patient comfort and performance.

Strategic collaborations with healthcare providers and a global presence fortify market positions. Emerging players contribute to market dynamics, introducing niche products. As the demand for ligament stabilizers rises due to sports injuries and orthopedic conditions, competition intensifies, fostering a dynamic environment of technological innovation and diverse product offerings. Some prominent manufacturers are as follows:

  • Ossur hf
  • DJO Global Inc.
  • Bauerfeind AG
  • Breg Inc.
  • BSN Medical GmbH
  • DeRoyal Industries Inc.
  • Otto Bock Healthcare GmbH
  • 3M Company
  • medi GmbH & Co. KG
  • THUASNE SA

Ligament Stabilizer Market Growth Drivers & Trends

  • Increasing sports activities contribute to a growing demand for ligament stabilizers to manage and prevent injuries, driving market growth.
  • Innovations in lightweight and durable materials enhance the design and effectiveness of ligament stabilizers, improving patient comfort and compliance.
  • Growing aging population globally fuels the prevalence of ligament-related issues, boosting the adoption of stabilizing devices for enhanced joint support.
  • The trend towards minimally invasive procedures drives the development of advanced ligament stabilizers, aligning with patient preferences for less invasive treatment options.
  • Increasing focus on personalized healthcare leads to the development of customizable ligament stabilizers, catering to individual patient needs and improving treatment outcomes.

Unlock Growth Potential in Your Industry! Download PDF Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=38513

Global Ligament Stabilizer Market: Regional Profile

  • In North America, the ligament stabilizer market is propelled by a proactive approach to sports injuries and a robust healthcare infrastructure. Key players such as DJO Global and Össur North America dominate with innovative stabilizer solutions, catering to the region’s sports-centric lifestyle.
  • In Europe, a high prevalence of orthopedic conditions and a strong emphasis on injury prevention drive market growth. Companies like Bauerfeind AG and medi GmbH & Co. KG lead with a focus on quality and patient-centric designs, aligning with Europe’s healthcare standards.
  • The Asia Pacific witnesses a surge in ligament stabilizer adoption, fueled by a rising awareness of sports-related injuries and an expanding middle-class population. Local players and global leaders like Breg, Inc. capitalize on this growth, offering a diverse range of stabilizers to meet the region’s evolving orthopedic needs.

Ligament Stabilizer Market: Key Segments
By Injury Type

By Sales Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Sales

By Product Type

  • Knee Braces & Supports
  • Foot and Ankle Braces & Supports
  • Shoulder Braces & Supports
  • Spinal Orthoses
  • Wrist & Hand Braces & Supports

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA

Buy this Premium Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=38513&ltype=S

More Trending Report by Transparency Market Research:

Arthroscopic Visualization Instrument Market (関節鏡視下装置市場) – The global market stood at US$ 2.1 Bn in 2022 and is projected to reach US$ 3.8 Bn by 2031.

Non-invasive Prenatal Testing Market (سوق اختبارات ما قبل الولادة غير الجراحية) – The industry was valued at US$ 2.1 Bn in 2022. It is estimated to grow at a CAGR of 14.8 % from 2022 to 2031 and reach US$ 8.4 Bn by the end of 2031.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com    
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter| Blog | YouTube


Primary Logo

Market News and Data brought to you by Benzinga APIs

Nasopharyngoscope Market Expected to Reach US$ 813.4 Million with Growing at an 8.1% CAGR by 2034 | Fact.MR Report

Rockville, MD, Nov. 18, 2024 (GLOBE NEWSWIRE) — According to Fact.MR, a market research and competitive intelligence provider, the global nasopharyngoscope market is estimated to reach a valuation of US$ 373.3 million in 2024 and is expected to grow at a CAGR of 8.1% during the forecast period of (2024 to 2034).

The global nasopharyngoscope market is set to see remarkable growth spur further by the increasing demand for minimally invasive diagnostic techniques in ENT treatment. Due to rising cases of respiratory diseases, chronic sinusitis, sleep apnea, and other related conditions, nasopharyngoscopes-face increasing demand for them as key instruments used in looking at and diagnosing nasal passages, pharynx, and larynx conditions.

Market is driven by technological advancements in product development, increased adoption of video nasopharyngoscopes, and healthcare expenditure. Growing demand for such devices is also connected with increases in the global geriatric population and a rise in outpatient and office-based ENT procedures where such equipment is in common use.

The introduction of advanced systems by major medical device companies has led to some newsworthy market developments in terms of new partnerships and product launches. One such recent development involves the partnership between major healthcare companies in developing next-generation diagnostic nasopharyngoscopes that would allow for real-time imaging, further improving the precision and safety of the patient. Such innovations address the increasingly complex nature of upper respiratory tract disorders, enabling clear pathways toward more sensitive, non-invasive diagnostics

Ongoing innovation within the imaging technology, whereby integration of high-definition cameras together with features such as real-time video has considerably increased the diagnostic capability of the nasopharyngoscopes. Other companies are trying to manufacture systems that are much more compact and available at low cost while being easy to operate, hence extending their usability in office-based infrastructure and community clinics.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=10429 

There is an emerging prevalence of chronic sinusitis, sleep apnea disorders, and allergic rhinitis, which demands efficient diagnostic tools. The rise in the geriatric population along with other environmental factors such as pollution has contributed to a rise in upper respiratory diseases, thus boosting demand in the market.

Less invasive diagnostic procedures now characterize the new standard of care in otolaryngology, given the reduced risk, faster recovery time, and comfort for the patients. The nasopharyngoscope, especially the diagnostic type, has been an invaluable tool in outpatient clinics and has tended to minimize the use of more invasive surgical alternatives.

Most the developing regions are investing in healthcare infrastructure. Parts of Asia and Latin America are such geographies that are investing in healthcare infrastructure development. Such infrastructural growth, coupled with increasing access to higher-end medical devices, is likely to drive adoption of nasopharyngoscope across hospitals and diagnostic centres in these markets

Key Takeaways from Market Study

  • The global nasopharyngoscope market is projected to grow at 1% CAGR and reach US$ 813.4 million by 2034
  • The market created an opportunity of US$ 70.2 million growing at a CAGR of 8% between 2019 to 2023
  • North America is a prominent region that is estimated to hold a market share of 6% in 2034
  • Predominating market players include Olympus Corporation, Fujifilm Holdings Corporation, and Karl Storz SE & Co. KG.
  • Reusable nasopharyngoscopes under usage type are estimated to grow at a CAGR of 1% creating an absolute $ opportunity of US$ 385.1 million between 2024 and 2034

“Advancements in digitalization and minimally invasive procedures to boost global market demand” says a Fact.MR analyst.

Leading Players Driving Innovation in the Nasopharyngoscope Market:

Medtronic plc; Stryker Corporation; Boston Scientific Corporation; Richard Wolf GmbH; Cook Medical Incorporated; Olympus Corporation; Fujifilm Holdings Corporation; Karl Storz SE & Co. KG; Entellus Medical (Stryker Corporation); Smith & Nephew plc; Ambu A/S; Conmed Corporation; Happersberger otopront GmbH; EndoMed Systems GmbH.; Other Prominent Players.

Market Development:

With recent strategic collaborations and product launches, some of the leading companies are well placed to capture the nasopharyngoscope market.

ABC Medical Technologies has just introduced a new generation of video nasopharyngoscope with integrated AI diagnostic capabilities that will help ENT specialists find abnormalities in real time. Such a step is not surprising, as it corresponds with the ambitions of the company to become a global leader in endoscopy technology by 2026.

In light of the above, collaboration by DEF Healthcare Systems with XYZ Diagnostics to jointly develop a new range of disposable nasopharyngoscopes targeted at community clinics and ambulatory centers is functional. The product line focuses on the benefit of reduction in cross-contamination risks that is driving demand for single-use medical devices within outpatient care.

Nasopharyngoscope markets continue to present growth opportunities; companies establish ambitious yet achievable goals to capture more market share.

Large companies are beginning to target growth markets in Asia-Pacific and Latin America due to increased development in the healthcare infrastructure of these regions. Partnerships with local distributors and healthcare providers enable manufacturers to reach such high-growth markets. For instance, DEF Healthcare Systems plans to achieve 15% market share in Southeast Asia within the next three years by co-operating with the partner and producing products to their likings.

Companies are developing new product lines targeting various end-user segments, such as hospitals, diagnostic centers, and office-based procedures. The focus on the development of reusable and disposable varieties allows manufacturing companies to target cost-sensitive institutions, as well as infection-conscious ones. For example, ABC Medical Technologies plans to launch a wide range of reusable and disposable nasopharyngoscopes before the end of 2025 to meet wider market requirements.

A lot of investment is being laid in integrating AI and machine learning into nasopharyngoscopes. AI-based systems are already used by companies to support early detection, facilitating better diagnostic precision for ENT conditions. DEF Healthcare Systems is set to introduce an AI diagnostic system that would alter the use of nasopharyngoscope in office-based and hospital settings by 2028.

Major manufacturers are eyeing a 20% increase in global market share by 2030, driven by aggressive marketing strategies, product launches, and expansion into new geographies, especially emerging economies where healthcare expenditure is on the rise.

The growth of the nasopharyngoscope market is foreseen to continue further, wherein strategies related to innovation and expansion would play an imperative role. As companies begin to internally strengthen their product portfolios and utilize new technologies, the segment could only reach new heights by 2032. Some major focus areas of the leading players in the industry for recent developments include AI integration, product diversification, and geographical expansion.

Nasopharyngoscope Industry News:

  • In July 2022, The EES 100 is a nasopharyngoscope from Medimaging Integrated Solution Inc., which has secured FDA approval. This is a flexible nasopharyngoscope with completely integrated LEDs and a micro camera module that find their application in minimally invasive procedures.
  • In June 2021, Fujifilm Corporation Announced system integration platform designed exclusively for endoscopy suite including a nasopharyngoscope, to improve image and data integration in the endoscopy suite.

Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=S&rep_id=10429 

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the global nasopharyngoscope market, presenting historical data for 2019 to 2023 and forecast statistics for 2024 to 2034.

The study reveals essential insights on the basis of the global nasopharyngoscopes market analysis, by product type systems (flexible nasopharyngoscopes, [flexible video nasopharyngoscopes, flexible fiberoptic nasopharyngoscopes], rigid nasopharyngoscopes [rigid video nasopharyngoscopes, rigid fiberoptic nasopharyngoscopes]), accessories (light sources, sheaths and cannulas, biopsy forceps, suction catheters, insufflation tubes, video cables and connectors, cleaning and sterilization systems, monitor and display systems, irrigation systems, endoscope holders), by application (diagnostic nasopharyngoscopes [nasal obstructions evaluation, chronic/recurrent sinusitis & rhinitis, adenoid hypertrophy, vocal cord and laryngeal disorders, sleep apnea evaluation, epistaxis detection, tumor detection] surgical nasopharyngoscopes [endoscopic sinus surgery, adenoidectomy, nasopharyngeal tumors biopsy and removal, septoplasty, laser-assisted uvulopalatopharyngoplasty (LAUP), foreign body removal, epistaxis cauterization, nasal bones and cartilage repair surgery, turbinate reduction surgery), by usage type (reusable nasopharyngoscopes and disposable nasopharyngoscopes), by end user (hospitals, diagnostic centers, office-based settings, ambulatory surgical centers, community/specialty clinics) and across major regions of the world (North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia, and Pacific, Middle East & Africa).

Checkout More Related Studies Published by Fact.MR Research: 

The global prescription delivery service market is estimated to touch a valuation of US$ 192.32 million in 2024. The market has been forecasted to expand at a CAGR of 14.3% to achieve a size of US$ 734.15 million by the end of 2034.

According to a new industry report released by Fact.MR, turnover of the global endovascular stent market is estimated at US$ 1.32 billion in 2024 and is forecasted to expand at 8.5% CAGR to achieve a value of US$ 2.99 billion by the end of 2034.

Fact.MR in its new report stated that the global ceftriaxone sodium (API) market is estimated to touch a valuation of US$ 339.44 million in 2024 and is further forecasted to reach a value of US$ 821.62 million by 2034-end. Demand is projected to increase at a notable CAGR of 9.2% throughout the projection period (2024 to 2034).

The global Cas9 nuclease market is estimated at US$ 217.95 million in 2024. The market has been projected to rise at a double-digit CAGR of 14.6% and reach a size of US$ 854.97 million by the end of 2034.

The Global Factor XIII Deficiency Treatment Market will be valued at US$ 210.3 million in 2023 and has been forecasted to expand at a noteworthy CAGR of 5.8% to end up at US$ 400.7 Million by 2034.

About Us: 

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning. With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape.  

Contact: 
US Sales Office: 
11140 Rockville Pike 
Suite 400 
Rockville, MD 20852 
United States 
Tel: +1 (628) 251-1583 
Sales Team: sales@factmr.com 
Follow Us:LinkedIn | Twitter | Blog  


Primary Logo

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Rotating Equipment Repair Market is Expected to Expand at a CAGR of 5%, Reaching US$ 32,047.2 Million by 2034 | Fact.MR Report

Rockville, MD , Nov. 18, 2024 (GLOBE NEWSWIRE) — The global Rotating Equipment Repair Market is estimated to reach US$ 19,674.2 million in 2024 and expand at a steady 5% CAGR through 2034. The market is forecast to attain a valuation of US$ 32,047.2 million by 2034.

Growth in industrial sectors like manufacturing, energy, and petrochemicals is raising the demand for rotating equipment repairs for uninterrupted operations. Additionally, aging infrastructure and machinery also necessitate frequent maintenance and repairs for a better lifespan.

Surging use of preventive maintenance strategies is increasing the demand for regular inspection and repair services. Further, the implementation of strict environmental regulations to meet the current emission standards and lower energy consumption is also increasing the applications of rotating equipment repair services.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=9670            

                               
Key Takeaways from the Rotating Equipment Repair Market Study:

  • The global rotating equipment repair market gained US$ 15,628.4 million in 2019.
  • The North America market is expected to capture a significant market share of 31.9% in 2024. In the same year, the market is estimated to be valued at US$ 6,276.1 million in 2024. By 2034, the regional market is forecast to amass US$ 10,639.7 million.
  • The East Asia market is predicted to acquire a value share of 22.9% in 2024. The regional market is forecast to be worth US$ 8,300.2 million by 2034, expanding at a CAGR of 6.3%.
  • Direct OEM-based is a leading sales channel for rotating equipment repairs. The segment is anticipated to occupy a value share of 63.3% in 2024. The segment is projected to record a 5.4% CAGR and reach US$ 20,990.9 million by 2034.
  • Centrifugal compressors are the dominantly purchased equipment. The segment is expected to capture 27.8% in 2024. The segment is projected to expand at a CAGR of 5% to gain US$ 8,941.2 million by 2034.

“Players are expected to observe significant opportunities in the East Asia market as power needs increase in this region. Moreover, manufacturers are also focusing on developing distinct repair technologies and materials to reduce downtime, increase efficiency, and prolong equipment’s lifespan.” says a Fact.MR analyst.

Leading Players Driving Innovation in the Rotating Equipment Repair Market:

Key players in the rotating equipment repair market include John Wood Group PLC, Sulzer AG, Ebara Corporation, KSB SE & Co. KGaA, Siemens AG, General Electric Company, Flowserve Corporation, The Weir Group PLC, Maintenance Partners NV, De Pretto Industrie S.r.l., Rainbow Mechanical Solutions LLC, Amaru Giovanni S.R.L., Triple EEE, Hydro Inc., Stork, MAN ES, Torishima Pump Mfg. Co., Ltd., TS&S, CFATEC, MEOS CO. LLC, Basis Plant Services S.r.l., Al-Rushaid Group, and S.T. Cotter Turbine Services, Inc., among others.

Competitive Landscape:

Key players are increasing their repair service offerings for a wide variety of rotating equipment. These offerings include specialized services such as predictive maintenance and remote monitoring. Additionally, players are increasing their penetration in new markets, especially in developing regions with significant demand for power generation and infrastructure.

Market leaders are additionally collaborating with technology providers, OEMs, and other active players to access new technologies and markets.

Key competitors are further investing their resources in inorganic growth strategies, like joint ventures, mergers, and acquisitions, to increase their market share.

Recent Developments Shaping the Rotating Equipment Repair Market:

  • In April 2022, Sulzer expanded the availability of superior-quality services for rotating equipment in Gujarat, India. The service center is going to offer retrofits, upgrades, repairs, and parts manufacturing for an extensive range of rotating equipment repairs.
  • In October 2023, API enhanced the oil and gas sector’s safety with revised recommended practices for the components of rotating equipment.

Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=S&rep_id=9670                               

Rotating Equipment Repair Industry News:

  • In June 2020, Blackstone Industrial Services, a prominent rotating equipment services provider in Canada, declared that it will buy the assets of Trican Pipeline & Industrial Services Business. Increasing competitiveness in the primary market was the primary goal of this transaction.
  • In 2023, Siemens will offer a digital twin for machine tool processing on the Siemens Xcelerator Marketplace in partnership with DMG?MORI. It is anticipated that this will allow for innovations and improvements in time-to-market, sustainability, and flexibility.

Segmentation of Rotating Equipment Repair Market Research:

  • By Sales Channel :
    • Direct OEM-based
    • Independent Service Vendor-based
  • By Equipment :
    • Pumps
    • Centrifugal Compressors
    • Agitator and Mixers
    • Turbines
    • Gas Turbines
    • Steam Turbines
  • By Region :
    • North America
    • Europe
    • Latin America
    • East Asia
    • South Asia and Oceania
    • The Middle East and Africa

Checkout More Related Studies Published by Fact.MR Research: 

Automotive Pumps Market: The global automotive pumps market is forecasted to expand at a CAGR of 4.6% and touch a valuation of US$ 23.48 billion by the end of 2033, up from US$ 14.99 billion in 2023.

Automotive Collision Repair Service Market: The global automotive collision repair service market has been calculated at a value of US$ 195.27 billion for 2024 and is forecast to reach a value of US$ 272.8 billion by 2034, with a projected CAGR of 3.4% from 2024 to 2034.

Automobile Engine & Part Manufacturing Market: Revenue from the global automobile engine & part manufacturing market is analyzed at US$ 410.21 billion in 2024. The market is projected to increase at a remarkable 8.3% CAGR and reach a size of US$ 912.97 billion by the end of 2034.

Auto Part & Accessory Manufacturing Market: The latest study by Fact.MR reveals that the global auto part & accessory manufacturing market is estimated to rise from US$ 1997.45 billion in 2024 to US$ 3879.15 billion by 2034-end. Demand is evaluated to expand at a 6.9% CAGR between 2024 and 2034.

Autonomous Farm Equipment Market: Forecasted to advance at 15.3% CAGR over the next 10 years, the global autonomous farm equipment market is anticipated to increase from a value of US$ 1.1 billion in 2024 to US$ 4.59 billion by 2034, as revealed in the recently updated industry report by Fact.MR.

About Us: 

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.

With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape.  

Contact: 
US Sales Office: 
11140 Rockville Pike 
Suite 400 
Rockville, MD 20852 
United States 
Tel: +1 (628) 251-1583 
Sales Team: sales@factmr.com 
Follow Us:LinkedIn | Twitter | Blog


Primary Logo

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.